- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Patent holdings for IPC class C07D 417/14
Total number of patents in this class: 9355
10-year publication summary
728
|
700
|
645
|
715
|
694
|
742
|
693
|
705
|
784
|
216
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 5080 |
297 |
Merck Sharp & Dohme LLC | 3689 |
195 |
Novartis AG | 11238 |
162 |
F. Hoffmann-La Roche AG | 7958 |
160 |
Janssen Pharmaceutica N.V. | 3839 |
160 |
Takeda Pharmaceutical Company Limited | 2961 |
157 |
Boehringer Ingelheim International GmbH | 4629 |
146 |
Gilead Sciences, Inc. | 1879 |
124 |
Amgen Inc. | 3779 |
118 |
Merck Patent GmbH | 5909 |
103 |
Hoffmann-La Roche Inc. | 3060 |
92 |
Syngenta Participations AG | 4970 |
81 |
Dana-Farber Cancer Institute, Inc. | 2455 |
81 |
AstraZeneca AB | 3042 |
76 |
Abbvie Inc. | 1808 |
73 |
Rigel Pharmaceuticals, Inc. | 613 |
72 |
Genentech, Inc. | 3742 |
71 |
Vertex Pharmaceuticals Incorporated | 1581 |
67 |
Shionogi & Co., Ltd. | 914 |
66 |
LG Chem, Ltd. | 17205 |
64 |
Other owners | 6990 |